甘露醇对需肾上主动脉阻断的慢性肾脏病患者具有肾脏保护作用
本研究基于血管外科学会质量倡议数据库,分析2003至2020年间择期开放腹主动脉瘤修复且近端阻断位于至少一侧肾动脉以上的患者。结果显示,在合并慢性肾脏病的患者中,使用甘露醇与术后透析风险降低相关(单因素P=0.005,多因素P=0.008);而在无慢性肾脏病的患者中未见肾脏保护作用。
要点
- 在合并慢性肾脏病(Cr>1.8 mg/dL)的患者中,甘露醇使用与术后透析风险降低相关(多因素P=0.008)。
- 在无基线慢性肾脏病的患者中,甘露醇未显示肾脏保护作用。
- 延长缺血时间(超过40分钟)与无慢性肾脏病患者术后透析风险升高相关,但在慢性肾脏病患者中不显著。
核心结论
- 在合并慢性肾脏病且需肾上主动脉阻断行开放腹主动脉瘤修复的患者中,甘露醇使用与术后需要血液透析的风险降低相关。
- 作者认为,在适当选择的患者中,尤其是存在基础肾功能不全者,甘露醇可能在需要肾上阻断的肾旁腹主动脉瘤开放修复中提供肾脏保护作用。
研究设计与样本
- 研究查询了血管外科学会质量倡议数据库,纳入2003年至2020年间所有择期开放腹主动脉瘤修复患者。
- 纳入当前分析的条件为近端主动脉阻断位置在至少一侧肾动脉以上。
- 慢性肾脏病定义为肌酐(Cr)> 1.8 mg/dL。
- 主要终点为30天主要并发症(心肌梗死、呼吸系统并发症、下肢或肠道缺血、需要临时或永久血液透析)和死亡率。
- 比较了甘露醇组与非甘露醇组,并按是否存在既存慢性肾脏病进行分层。
主要发现
- 研究期间共4156例患者接受择期开放腹主动脉瘤修复,需要阻断位置超过一侧肾动脉者占32.7%,超过双侧肾动脉者占67.3%;182例(4.4%)存在既存慢性肾脏病。
- 总体上,69.8%的患者在手术期间接受了甘露醇。
- 甘露醇在阻断位置高于双侧肾动脉的病例中使用更频繁(70.3%),高于单侧肾动脉者为61.5%。
- 在无慢性肾脏病的患者中,延长缺血时间(超过40分钟)与术后透析风险升高相关;但在基线慢性肾脏病患者中不显著。
- 在慢性肾脏病患者中,单因素分析显示甘露醇使用与术后透析风险降低相关(P = 0.005),多因素分析中仍显著(P = 0.008)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mannitol is often administered during open juxtarenal or suprarenal aortic surgery to prevent ischemic injury to the kidneys. Prior evidence evaluating the benefits of intraoperative mannitol in reducing ischemia/reperfusion injury is conflicting and largely based on small, retrospective series. The aim of this study was to evaluate the effect of mannitol in preventing postoperative hemodialysis in patients undergoing open abdominal aortic aneurysm (AAA) repair where proximal control involved temporary renal ischemia. METHODS: The Society for Vascular Surgery Quality Initiative database was queried for all patients undergoing elective open AAA repair between 2003 and 2020. Patients were included in the current analysis if the proximal aortic clamp was placed above at least one renal artery. Chronic kidney disease (CKD) was defined as Cr > 1.8 mg/dL. Primary end points were 30-day major morbidity (myocardial infarction, respiratory complications, lower extremity or intestinal ischemia, and the need for temporary or permanent hemodialysis) and mortality. Comparisons were made between the mannitol and nonmannitol cohorts and stratified by the presence of preexisting CKD. RESULTS: During the study period, 4,156 patients underwent elective open AAA repair requiring clamp placement more than one (32.7%) or both (67.3%) renal arteries; 182 patients (4.4%) had preexisting CKD. Overall, 69.8% of patients received mannitol during their surgery. Mannitol was more frequently used in cases involving clamp placement above both renal arteries (70.3%) than one renal artery (61.5%). While prolonged ischemia time (more than 40 min) was associated with a higher risk of postoperative dialysis in patients without CKD, it was not significant in patients with baseline CKD. On a univariate analysis, mannitol use in patients with CKD was associated with a lower risk of postoperative dialysis (P = 0.005). This remained significant on a multivariate analysis (P = 0.008). Mannitol use did not appear to confer renal protective effects in patients without baseline CKD. CONCLUSIONS: Mannitol use was associated with a decreased risk of need for postoperative hemodialysis in patients with CKD undergoing suprarenal aortic clamping for open aneurysm repair. In appropriately selected patients, particularly those with underlying renal insufficiency, mannitol may confer a renal protective effect in open repair of pararenal AAA requiring suprarenal clamping.
引用
- Teter K, Rockman C, Patel V, et al. Mannitol Use is Renal Protective in Patients with Chronic Kidney Disease Requiring Suprarenal Aortic Clamping. Ann Vasc Surg. 2022. PMID: 35452789. doi:10.1016/j.avsg.2022.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。